Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
I'm sorry, but you haven't provided the article that needs to be enriched with an "InvestingPro Insights" section. Could you please provide the article text or context so that I can assist you accordingly?
In other recent news, TransCode Therapeutics, a biopharmaceutical company, is facing potential delisting from Nasdaq due to non-compliance with the minimum bid price and equity requirements. TransCode has appealed this decision, and the process is currently pending a final decision by the Nasdaq Hearings Panel. The company also announced plans for a public stock offering with ThinkEquity serving as the sole placement agent. The offering aims to advance product development, especially for its lead therapeutic candidate, TTX-MC138.
TransCode Therapeutics has reported promising results from its Phase 0 trial of TTX-MC138, an RNA-based cancer drug. The drug demonstrated potential anti-tumor activity and a significant reduction in the molecular target miRNA-10b. The FDA has authorized the company to commence a Phase 1/2 clinical trial for TTX-MC138.
In the company's recent Annual Meeting of Stockholders, four directors were elected and an amendment to increase shares for issuance under the company's 2021 Stock Option and Incentive Plan was approved. However, a proposal for a reverse stock split was rejected by stockholders. These are some of the recent developments at TransCode Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.